In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
The PROCEDE 500 study demonstrated that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).
A new study found substantial long-term reduction in mortality for men with localized prostate cancer who undergo a radical prostatectomy.
For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival for the majority of men who have not received treatment with curative intent.
Although patients with prostate cancer endorse multiple sources of information, they report greatest satisfaction with information from the treating physician about patient outcomes.
Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.
Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.
The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.
A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.
Three-dimensional biopsies find more prostate cancers, particularly in the anterior regions, than those guided by ultrasound, according to a new clinical study.
New evidence lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.
Men with prostate cancer on active surveillance should be informed of the risk of complications linked to repeated biopsies.
Results from PROCEDE 500, a clinical utility study with the Prolaris test, demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.
Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes.
Two beneficial treatment approaches are available for metastatic and locally advanced prostate cancer, according to two studies presented in advance of ASCO's annual Genitourinary Cancers Symposium.
Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.
Additional predictors guide selection of patients with prostate cancer for active surveillance programs.
Brisk walking before prostate cancer diagnosis has been associated with more regularly-shaped blood vessels.
Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated.
After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin demonstrated a significantly lower prostate cancer risk.
The methods used to anesthetize patients with prostate cancer and control pain due to surgical resection of the prostate glands for adenocarcinoma may affect patients' long-term cancer outcomes, a study has found.
In vivo BPA exposure has been tied to increased incidence of prostate intraepithelial neoplasia and adenocarcinoma.
A cell-surface protein called CD151 may serve as a biomarker that accurately predicts which patients with prostate cancer are likely to experience metastasis or recurrence.
With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.
Supplementing general anesthesia (GA) with neuraxial anesthesia during prostate cancer surgery is associated with improved oncological outcomes compared with GA alone.
Framework for optimizing CRPC treatment should involve joint management by both a urologist and a medical oncologist.
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.
Men with prostate cancer who take the cholesterol-lowering drugs known as statins are significantly less likely to die from their cancer than men who do not take such medication, according to a new study.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones. This study adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.
Fish oil consumption affects levels of pro-inflammatory molecules, omega fatty acids, measure of cancer growth.
Vesicles released from aggressive prostate cancer cells with highly migratory features, known as large oncosomes, may be a new source of biomarkers for aggressive prostate cancer.
Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of proinflammatory substances in their blood than men who ate a typical Western diet.
Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an intensity-modulated radiation therapy (IMRT)-based treatment strategy, according to a new study.
A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.
The flowing movements and meditative exercises of the mind-body activity known as Qigong may help survivors of prostate cancer to combat fatigue, according to a newly published trial study.
Men with prostate cancer who are overweight or obese at diagnosis are more likely to die from the disease than men who are of healthy weight, according to a newly published study.
For men with prostate cancer, postdiagnostic statin use is associated with a decreased risk of prostate cancer and all-cause mortality, with stronger effects seen for those who used statins before diagnosis, according to a study.
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over therapy, according to research.
The risk of melanoma was significantly increased with personal history of PCa, whereas the risk of non-melanoma skin cancer was marginally increased with PCa.
or men with prostate cancer, body mass index (BMI) at diagnosis is associated with mortality, according to a study.
Changes in circulating tumor cell levels may predict treatment outcomes in castration-resistant prostate cancer more accurately than changes in prostate-specific antigen levels, according to a study.
Biomarkers have been identified that vary with breast cancer progression, and short telomere length associated with increased risk of aggressive prostate cancer.
Potential psychological harm associated with biopsy even in absence of cancer diagnosis
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
Serum free fatty acids and metabolites are one- to six-fold higher in patients with lung or prostate cancer.
Hot flashes occur in approximately 80% of men who are undergoing hormone manipulation as treatment for prostate cancer. However, neither soy protein nor a common antidepressant provides relief from hot flashes for men.
Men with intermediate-risk prostate cancer who received long-term hormonal therapy (HT) after radiation had no additional benefits compared to short-term hormonal therapy.
Men with mCRPC who had not undergone previous chemotherapy reported delayed pain progression and prolonged health-related quality of life with abiraterone acetate plus prednisone, compared with prednisone alone.
Biopsy-related procedures accounted for much of the prostate cancer screening costs.
These tools can help clinicians determine which treatments are ideal and explain to patients what their best options are and why.
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have set forth several recommendations on radiation therapy after prostatectomy.
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to new research.
Gleason score upgrade or non-organ confined cancer is double for men with low risk prostate cancer.
Lifestyle intervention tied to increases in telomere length in men with low-risk prostate cancer.
UroLift system, a permanent implant, has been approved by the U.S. Food and Drug Administration to treat low or blocked urine flow in men aged 50 and older.
Gleason 8 tumors have a substantially better prognosis after radical surgery than Gleason 9 and 10 tumors.
Researchers have identified a gene signature that is expected to help predict which low-risk prostate tumors will become lethal.
Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.
New research has found that the androgen-synthesizing enzyme 3βHSD1 has a mutation that enables a tumor to make its own supply of androgens, which are the hormones that fuel the growth of prostate cancer.
The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.
After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.
Higher coffee consumption is linked to lower risk of prostate cancer recurrence/progression.
A team of researchers has identified a key mechanism behind aggressive prostate cancer.
A large-scale analysis of the association between DNA viruses and human malignancies suggests that many of the most common cancers are not associated with DNA viruses
Finasteride is linked to reduction in the risk of prostate cancer, but no decrease in mortality over 18 years, per a recent study.
The rate of inappropriate cancer scans for low-risk prostate cancer patients in Sweden plummeted in the decade following a joint campaign to curtail such tests. The campaign was run by the Swedish County Councils and the National Prostate Cancer Register (NPCR) of Sweden
Promising initial results for 10 patients with recurrent prostate cancer after radiation
Radium-223 dichloride (Xofigo) significantly improved overall survival and caused few adverse events in men with castration-resistant prostate cancer (CRPC) that had metastasized to bone, researchers reported.
Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality.
Androgen deprivation therapy (ADT) was significantly associated with an increased risk for acute kidney injury in a large study of men with nonmetastatic prostate cancer.
New research indicates that eating a modest amount of walnuts can protect against prostate cancer.
An aid helps men with their decision making about prostate cancer screening, but the print and web-based aids do not affect screening rates.
Among men who had undergone radical prostatectomy, daily consumption of a soy protein supplement did not reduce or delay development of biochemical recurrence of prostate cancer
Most men in the United States report little shared decision making between them and their physicians in terms of choosing or declining to undergo prostate-specific antigen screening.
Nerves play a critical role in both the development and spread of prostate tumors.
Adherence to lifestyle recommendations can reduce risk of aggressive prostate cancer.
Only 23 and 27 percent of radiation oncologists and urologists use quality-of-life and life-expectancy instruments, respectively.
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk for acute kidney injury.
A Phase 3 randomized trial was halted when interim analysis showed radium-223 was superior to placebo used in combination with best standard of care in men with castration-resistant prostate cancer.
Androgen deprivation is associated with acute kidney injury in non-metastatic prostate cancer.
African American men with very-low-risk prostate cancer, and who meet criteria for active surveillance, but undergo immediate surgery are much more likely than men of other races to actually have aggressive disease.
A method has been developed to identify aggressive prostate cancers that require immediate therapy.
No reduction in biochemical recurrence within two years of radical prostatectomy, despite daily soy protein ingestion.
Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" and have better QoL while reducing health care costs, according to a new study.
The vast majority of oncology clinical practice guidelines (CPGs) fail to meet the Institute of Medicine (IOM) standards for trustworthy guidelines, according to a recent evaluation published by Journal of Clinical Oncology.
A device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy has the potential to significantly reduce rectal injury.
Use of advanced treatment technologies is up in men at low risk of diagnosed with prostate cancer.
Regular aspirin only lowers risk of BRAF-wild-type colorectal cancer, according to a study by the Journal of the American Medical Association.
Simultaneously combining positron emission tomography (PET) and magnetic resonance (MR) has a higher capacity to map recurrent prostate cancer than the already high standard of integrated PET and computed tomography (CT), according to research.
The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.
Researchers at The University of Texas Southwestern Medical Center in Dallas, Texas, have developed a class of drugs known as peptidomimetics, which disrupt androgen receptor activity in a unique way.
Worse outcomes are seen for African-American men with low-risk prostate cancer who undergo prostatectomy, according to a study published online in the Journal of Clinical Oncology.
Finding in men with similar prostate conditions undergoing watchful waiting versus immediate surgery proved to be similar.
Integrated prostate cancer centers have greater use of intensity modulated radiation therapy and lower use of androgen deprivation therapy, when compared to urology practices.
Chemists at the University of California-Irvine (UC Irvine) have developed a technology to identify clinically usable markers for prostate cancer in urine.
Next generation genomic analysis has determined that some of the more aggressive prostate cancers have similar genetic origins, according to a recent publication
Replacement of 10 percent of carbohydrates with vegetable fat cuts lethal prostate cancer risk and also all-cause mortality.
FDA-related news items of relevance from the month of May, 2013.
Survivors of cancer with depressive symptoms were twice as likely to die prematurely as survivors who were not depressed, a prospective study demonstrated.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|